Wednesday, December 8, 2021
HomeLatest Pharma-NewsBayer and Evotec form a new strategic alliance focusing on the treatment...

Bayer and Evotec form a new strategic alliance focusing on the treatment of polycystic ovary syndrome

Jan 09, 2020: Evotec SE and Bayer AG announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”).

As per  the terms of the agreement, both companies will contribute drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options. The strategic alliance will also have access to the targets from the recently formed partnership between Celmatix and Evotec.

- Advertisement -

Celmatix is the world leader in big data-driven target discovery that focuses on fertility and women’s health. “PCOS is a common, underdiagnosed and undertreated disease among women, with several serious co-morbidities.”

Evotec will receive € 6.5 m direct payment and € 10 m research payments over five years.

In addition, Evotec might be eligible in order  to receive pre-clinical, clinical and sales milestones of potentially over € 330 m as well as royalties up to low double-digit percentages of net sales.

In 2012, Bayer and Evotec entered their first strategic five-year, multi-target alliance. The collaboration was productively completed resulting in three clinical and one pre-clinical drug candidate currently advancing during development for the treatment of endometriosis.

A second research alliance was initiated in 2016 to develop multiple clinical candidates for the treatment of kidney diseases. https://www.evotec.com/en/invest/news–announcements/p/bayer-and-evotec-form-new-strategic-alliance-focusing-on-polycystic-ovary-syndrome-5893

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular